Wondering if people bothered checking Japan and current European partner sales before getting excited about potential future global sales. All the things currently on tap are fine and well but likely won't have any real impact on revenue for 2-3 years. I personally would make book on Permeaderm untimately being an Avita shareholder tax write off. How about we focus on getting burns and traumatic wounds up to their very lucrative potential.
ReCell Go Is Massive, page-117
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.19 |
Change
0.110(3.57%) |
Mkt cap ! $224.8M | |||
| Open | High | Low | Value | Volume |
| $3.17 | $3.19 | $3.12 | $359.6K | 113.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 793 | $3.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.19 | 2221 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |